Lvw Advisors, LLC Outlook Therapeutics, Inc. Transaction History

Lvw Advisors, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 22, 2022	SELL	$0.91 - $2.01 $9,100 - $20,099	-10,000 Reduced 0.57%	1,733,633 $1.77 Million
Q3 2020 Oct 29, 2020	BUY	$0.61 - $1.6 $651,765 - $1.71 Million	1,068,468 Added 158.25%	1,743,633 $1.26 Million
Q2 2020 Aug 11, 2020	BUY	$0.56 - $1.41 $133,536 - $336,225	238,458 Added 54.6%	675,165 $871,000
Q4 2019 Feb 10, 2020	BUY	$0.53 - $1.59 $25,238 - $75,714	47,619 Added 12.24%	436,707 $258,000
Q3 2019 Oct 22, 2019	BUY	$1.32 - $2.63 $140,306 - $279,550	106,293 Added 37.59%	389,088 $580,000
Q2 2019 Aug 14, 2019	BUY	$0.91 - $7.68 $257,343 - $2.17 Million	282,795 New	282,795 $588,000

31.5K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $520M
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Lvw Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Lvw Advisors, LLC with notifications on news.